Incidence and risk factors of major toxicity associated to first-line antituberculosis drugs for latent and active tuberculosis during a period of 10 years

Castro, Ana Tavares e; Mendes, Mariana; Freitas, Sara; Roxo, Paulo Cravo

doi:10.1016/j.rppnen.2014.08.004

Cited by 33 publications

(34 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In one small study, DM was associated with 2.5‐ and 3.9‐fold adverse drug effects, respectively, in intensive and continuation treatment phase in crude univariate analysis but the differences failed to reach statistical significance . DM was also associated with more adverse drug effects in univariate analysis in another two studies . Among the study that also attempted to adjust for gender, age and year of diagnosis, no significant independent effect was found but the best estimate of the effect size was 1.33, rather similar to the best estimate of 1.38 in the current study.…”

Section: Discussionsupporting

confidence: 55%

Effects of diabetes mellitus on the clinical presentation and treatment response in tuberculosis

et al. 2017

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 55%

Effects of diabetes mellitus on the clinical presentation and treatment response in tuberculosis

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The amount of free fraction of ATT crossing the blood ocular barriers and reaching various ocular structures is not clearly known, but from the therapeutic outcome and various ocular toxicities exerted by these drugs indicate that they reach the eye to some extent. 15 In addition, the role of ATT in cases where pathogenesis is considered purely immunogenic remains controversial. It is the ophthalmologist’s responsibility to monitor drug regimens to avoid ocular toxicity without compromising the ocular therapeutic effect of systemic TB therapeutics.…”

Section: Discussionmentioning

confidence: 99%

Anti-tubercular therapy for intraocular tuberculosis: A systematic review and meta-analysis

Kee

González‐López

Al-Hity

et al. 2016

Survey of Ophthalmology

View full text Add to dashboard Cite

Intraocular tuberculosis remains a diagnostic and management conundrum for both ophthalmologists and pulmonologists. We analyze the efficacy and safety of anti-tubercular therapy (ATT) in patients with intraocular tuberculosis and factors associated with favorable outcome. Twenty-eight studies are included in this review, with a total of 1,917 patients. Nonrecurrence of inflammation was observed in pooled estimate of 84% of ATT-treated patients (95% CI 79–89). There was minimal difference in the outcome between patients treated with ATT alone (85% successful outcome; 95% CI 25–100) and those with concomitant systemic corticosteroid (82%; 95% CI 73–90). The use of ATT may be of benefit to patients with suspected intraocular tuberculosis; however, this conclusion is limited by the lack of control group analysis and standardized recruitment and treatment protocols.

show abstract

“…Isoniazid (INH), rifampin (RIF), ethambutol (EMB) and pyrazinamide (PZA) for the initial 2‐month phase followed by INH and RIF for 4‐7 months is standard treatment for people at low risk for drug‐resistant disease . Long‐term anti‐TB combination regimens could lead to various types and levels of adverse drug reactions (ADRs), which could subsequently lead to discontinued or interrupted treatment, extended treatment time and increased risks of drug resistance, treatment failure and relapse . Anti‐TB drug‐induced liver injury (ATLI) is a serious ADR.…”

Section: What Is Known and Objectivementioning

confidence: 99%

Possible association of HMOX1 and NQO1 polymorphisms with anti-tuberculosis drug-induced liver injury: A matched case-control study

et al. 2019

View full text Add to dashboard Cite

Summary What is known and objective Reactive metabolites from anti‐tuberculosis (anti‐TB) drugs can result in abnormal accumulation of reactive oxygen species (ROS), which plays an important role in anti‐TB drug‐induced liver injury (ATLI). Liver cells could keep the production of ROS in balance by antioxidant activities. The heme oxygenase 1, encoded by the HMOX1 gene and NADH:quinone oxidoreductase 1, encoded by the NQO1 gene are crucial mediators of cellular defense against ROS. The present study aimed to investigate the associations between HMOX1 and NQO1 polymorphisms and ATLI in Chinese anti‐TB treatment population. Methods A matched case‐control study was conducted using 314 ATLI cases and 628 controls. Multivariate conditional logistic regression analysis was used to estimate the association between genotypes and risk of ATLI by the odds ratios (ORs) with 95% confidence intervals (CIs), with weight and use of hepatoprotectant as covariates. Results and discussion Patients carrying the GG genotype at rs2071748 in HMOX1 were at a higher risk of ATLI than those with the AA genotype (adjusted OR = 1.503, 95% CI: 1.005‐2.249, P = 0.047), and significant differences were also found under the recessive (P = 0.015) and additive (P = 0.045) models. Subgroup analysis confirmed the relationship in mild hepatotoxicity cases under the recessive and additive models (adjusted OR = 1.714, 95% CI: 1.169‐2.513, P = 0.006; adjusted OR = 1.287, 95% CI: 1.015‐1.631, P = 0.037, respectively). What is new and conclusion This is the first study to explore the relationship between HMOX1, NQO1 polymorphisms and ATLI in Chinese anti‐TB treatment population. Based on a matched case‐control study, genetic polymorphisms of HMOX1 may be associated with susceptibility to ATLI in the Chinese population.

show abstract

Incidence and risk factors of major toxicity associated to first-line antituberculosis drugs for latent and active tuberculosis during a period of 10 years

Cited by 33 publications

References 30 publications

Effects of diabetes mellitus on the clinical presentation and treatment response in tuberculosis

Effects of diabetes mellitus on the clinical presentation and treatment response in tuberculosis

Anti-tubercular therapy for intraocular tuberculosis: A systematic review and meta-analysis

Possible association of HMOX1 and NQO1 polymorphisms with anti-tuberculosis drug-induced liver injury: A matched case-control study

Contact Info

Product

Resources

About